Reply: An incomplete story
Beta-blockers reduced mortality in landmark, placebo-controlled trials of heart failure with a reduced left ventricular ejection fraction only for those in sinus rhythm rather than atrial fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% of target) and similar heart...
| প্রধান লেখক: | , , , |
|---|---|
| বিন্যাস: | Journal article |
| প্রকাশিত: |
Elsevier
2018
|
| _version_ | 1826259413851176960 |
|---|---|
| author | Cleland, JGF Flather, MD Altman, DG Kotecha, D |
| author_facet | Cleland, JGF Flather, MD Altman, DG Kotecha, D |
| author_sort | Cleland, JGF |
| collection | OXFORD |
| description | Beta-blockers reduced mortality in landmark, placebo-controlled trials of heart failure with a reduced left ventricular ejection fraction only for those in sinus rhythm rather than atrial fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% of target) and similar heart rate reductions (1). For patients in AF, neither baseline nor follow-up ventricular rate was associated with beta-blocker benefit, nor have trials comparing rate control intensity shown important differences in outcome, although slower rates may be associated with a worse prognosis (2). |
| first_indexed | 2024-03-06T18:49:29Z |
| format | Journal article |
| id | oxford-uuid:0fb84d4d-4e04-4b65-8559-60e2917fec95 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:49:29Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:0fb84d4d-4e04-4b65-8559-60e2917fec952022-03-26T09:52:38ZReply: An incomplete storyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0fb84d4d-4e04-4b65-8559-60e2917fec95Symplectic Elements at OxfordElsevier2018Cleland, JGFFlather, MDAltman, DGKotecha, DBeta-blockers reduced mortality in landmark, placebo-controlled trials of heart failure with a reduced left ventricular ejection fraction only for those in sinus rhythm rather than atrial fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% of target) and similar heart rate reductions (1). For patients in AF, neither baseline nor follow-up ventricular rate was associated with beta-blocker benefit, nor have trials comparing rate control intensity shown important differences in outcome, although slower rates may be associated with a worse prognosis (2). |
| spellingShingle | Cleland, JGF Flather, MD Altman, DG Kotecha, D Reply: An incomplete story |
| title | Reply: An incomplete story |
| title_full | Reply: An incomplete story |
| title_fullStr | Reply: An incomplete story |
| title_full_unstemmed | Reply: An incomplete story |
| title_short | Reply: An incomplete story |
| title_sort | reply an incomplete story |
| work_keys_str_mv | AT clelandjgf replyanincompletestory AT flathermd replyanincompletestory AT altmandg replyanincompletestory AT kotechad replyanincompletestory |